Legal Internship (Hybrid) jobs in United States
cer-icon
Apply on Employer Site
company-logo

Sobi - Swedish Orphan Biovitrum AB (publ) · 1 day ago

Legal Internship (Hybrid)

Sobi - Swedish Orphan Biovitrum AB (publ) is dedicated to developing innovative therapies for rare diseases. They are seeking a motivated Legal & Compliance Intern to support their Compliance Program and Legal Operations, offering hands-on experience in healthcare compliance, legal research, and training development.

BiotechnologyGeneticsMedicalPharmaceutical

Responsibilities

Support day-to-day operations of the compliance program
Provide general support for legal operations and contract management as needed
Conduct legal research and draft research memos on various healthcare compliance issues
Assist in creating training materials, including PowerPoint decks
Observe compliance trainings and monitoring activities

Qualification

Legal researchHealthcare complianceContract managementMicrosoft OfficeAnalytical skillsInterest in healthcare lawWritten communicationVerbal communication

Required

Current law student (1L or 2L preferred) or graduate student in a relevant field
Strong written and verbal communication skills
Excellent research and analytical skills
Interest in healthcare law, regulatory compliance, or legal operations
Proficiency in Microsoft Office, particularly PowerPoint and Word

Benefits

Competitive compensation for your work
Generous time off policy
Opportunity to broaden your horizons by attending popular conferences
Emphasis on work/life balance
Collaborative and team-oriented environment
Making a positive impact to help ultra-rare disease patients who are in need of life saving treatments

Company

Sobi - Swedish Orphan Biovitrum AB (publ)

twittertwitter
company-logo
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.

Funding

Current Stage
Public Company
Total Funding
$825.99M
2024-05-08Post Ipo Debt· $274.92M
2023-08-22Post Ipo Equity· $551.07M
2006-09-15IPO

Leadership Team

leader-logo
Guido Oelkers
Chief Executive Officer
Company data provided by crunchbase